Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma

Inclusion Criteria: * Histological diagnosis of ameloblastoma; all stages are eligible; patients must have evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria * B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E or other known dabrafenib sensitive BRAF mutation in tumor by any Clinical Laboratory Improvement Amendments (CLIA) certified lab; may include, for example, Sanger sequencing, SNaPshot platform, immunohistochemistry, Foundation One tests, etc.) * Life expectancy \> 3 months * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Absolute neutrophil count (ANC) \> 1.5 x10\^9/L * Platelet (PLT) \> 99 x 10\^9/L * Hemoglobin \> 8 g/dL * Total bilirubin (Tbili) \< 1.6 x upper limit of normal (ULN) * Aspartate aminotransferase (AST), alanine aminotransferase (ALT) \< 2.6 x ULN * Alkaline phosphatase (alk phos) \< 2.6 x ULN * Serum creatinine \< 1.6 x ULN or creatinine clearance \> 50 ml/min * Ability to understand and the willingness to sign a written informed consent document * Patients of childbearing potential must agree to use effective contraception until at least 6 months after treatment with dabrafenib * Able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels * Left ventricular ejection fraction equal to or greater than normal Exclusion Criteria: * No…